1-4 of 4
Laura Liao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma

CME Clinical Trials & Observations
Dai Chihara, Laura Liao, Joseph Tkacz, Anjali Franco, Benjamin Lewing, Karl M. Kilgore, Loretta J. Nastoupil, Lei Chen
Journal: Blood
Blood (2023) 142 (12): 1047–1055.
https://doi.org/10.1182/blood.2023020197
Published: 2023
Includes: Supplemental data
Journal Articles

Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy

Mehdi Hamadani, Laura Liao, Lauren Wilson, Amanda Howarth, Carlos Flores, Lei Chen
Journal: Blood
Blood (2022) 140 (Supplement 1): 8058–8060.
https://doi.org/10.1182/blood-2022-167753
Published: 2022
Journal Articles

Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US

Dai Chihara, Laura Liao, Joseph Tkacz, Benjamin Lewing, Anjali Franco, Karl M. Kilgore, Loretta J. Nastoupil, Lei Chen
Journal: Blood
Blood (2022) 140 (Supplement 1): 2421–2423.
https://doi.org/10.1182/blood-2022-163678
Published: 2022
Journal Articles

Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Jipan Xie, MD PhD, Aozhou Wu, PhD, Laura Liao, MS, Xiaoyan Du, MESc, Ahmed Noman, BA, Yawen Liang, PhD, Joseph Camardo, MD, Lei Chen, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-140136
Published: 2020